- Pyxis Oncology (PYXS, Financial) grants stock options to four new employees under the 2022 Inducement Plan.
- A total of 246,238 shares are covered by the options, with an exercise price of $1.10 each.
- 181,238 options vest over four years, while 65,000 options fully vest on December 31, 2025.
Pyxis Oncology (PYXS), a clinical-stage company focusing on next-generation antibody-drug conjugate therapeutics, recently announced inducement stock options for four newly hired employees. The options were granted under the company's 2022 Inducement Plan and approved by the Compensation Committee.
The options cover a total of 246,238 shares of common stock, with an exercise price set at $1.10 per share, reflecting the closing price on June 30, 2025. The options are structured into two tranches: 181,238 options will vest over four years, with 25% vesting after the first year and the remainder vesting monthly over the following 36 months. The remaining 65,000 options are set to vest fully on December 31, 2025.
These developments are part of Pyxis Oncology's strategy to attract and retain talent as it advances its pipeline of treatments for difficult-to-treat cancers. The company is actively developing its lead candidate, micvotabart pelidotin, in combination therapies to expand and strengthen its therapeutic portfolio.
